Literature DB >> 25915878

Antihypertensive treatment is not a risk factor for major cardiovascular events in the Gubbio residential cohort study.

Mariapaola Lanti1, Paolo E Puddu, Oscar Terradura Vagnarelli, Martino Laurenzi, Massimo Cirillo, Mario Mancini, Alberto Zanchetti, Alessandro Menotti.   

Abstract

BACKGROUND AND OBJECTIVES: Demonstration of antihypertensive beneficial role in population settings is difficult. Relationships of antihypertensive treatment, blood pressure control, risk factors and cardiovascular outcomes were investigated in the Gubbio study.
MATERIAL AND METHODS: Among 2248 cardiovascular disease-free men and women aged 35-74 years, individuals were classified as nonhypertensive, controlled hypertensive, uncontrolled hypertensive and untreated hypertensive based on cut-off limits of 140/90  mmHg for SBP/DBP and/or the use of antihypertensive drugs. End-point was the first major coronary, cerebrovascular or peripheral hard event [cardiovascular disease (CVD)] during a 15-year average. Univariate and multivariate analyses were run.
RESULTS: Nonhypertensive individuals were about 10 years younger and had lower risk factor levels than the other categories. The relative risk (and 95% confidence interval) for CVD versus nonhypertension was 1.78 (1.02-3.10) for controlled hypertension, 3.76 (2.79-5.06) for uncontrolled hypertension and 3.30 (2.59-4.21) for untreated hypertension (UTH). After adjusting for covariates, such as sex, age, achieved blood pressure and other risk factors, the CVD risk of controlled hypertension was practically equal to that of nonhypertension, and remained unchanged even when blood pressure was excluded from the model (1.03, 0.58-1.82). The higher cardiovascular risk of uncontrolled hypertension and UTH was reduced after adjusting for covariates, but remained significantly higher than in nonhypertension, with no significant differences between uncontrolled hypertension and UTH.
CONCLUSIONS: A higher level of baseline risk is not due to treatment per se, the risk being similar in uncontrolled hypertension and UTH. Adjustment for risk factors reduces the risk only in controlled hypertension, suggesting that there may be structural alterations scarcely reversible by antihypertensive treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25915878     DOI: 10.1097/HJH.0000000000000490

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

1.  Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study.

Authors:  Donghao Zhou; Bo Xi; Min Zhao; Liang Wang; Sreenivas P Veeranki
Journal:  Sci Rep       Date:  2018-06-20       Impact factor: 4.379

2.  Uncontrolled hypertension and associated factors among adult hypertensive patients in Ayder comprehensive specialized hospital, Tigray, Ethiopia, 2018.

Authors:  Gebrewahd Bezabh Gebremichael; Kalayou Kidanu Berhe; Teklewoini Mariye Zemichael
Journal:  BMC Cardiovasc Disord       Date:  2019-05-22       Impact factor: 2.298

3.  Prevalence, Awareness, Treatment, and Control of Hypertension and Its Associated Risk Factors: Results from Baseline Survey of SWADES Family Cohort Study.

Authors:  M D Saju; Komal Preet Allagh; Lorane Scaria; Shinto Joseph; Jotheeswaran Amuthavalli Thiyagarajan
Journal:  Int J Hypertens       Date:  2020-04-13       Impact factor: 2.420

4.  Trends of Prevalence of Uncontrolled Risk Factors for Cerebrocardiovascular Disease: Southern Italy from 1988/9 to 2008/9.

Authors:  Vincenzo Capuano; Norman Lamaida; Ernesto Capuano; Rocco Capuano; Eduardo Capuano; Gianfranco Mazzotta
Journal:  Cholesterol       Date:  2016-04-24

5.  Impact of Sex on Office White Coat Effect Tail: Investigating Two Italian Residential Cohorts.

Authors:  Xavier Humbert; Sophie Fedrizzi; Joachim Alexandre; Alessandro Menotti; Alain Manrique; Martino Laurenzi; Emmanuel Touzé; Paolo E Puddu
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.